Our COVID-19 vaccine agreements

New Zealand has signed agreements with 4 pharmaceutical companies to purchase COVID-19 vaccines, if they are proven to be safe and effective.

Latest updates

The Government has guaranteed that everyone in New Zealand will have access to the Pfizer/BioNTech vaccine. It has secured an additional 8.5 million doses, enough to vaccinate 4.25 million people.

Government purchases enough Pfizer vaccines for all New Zealanders

Vaccines we have agreed to purchase

Pfizer/BioNTech is now New Zealand’s primary vaccine provider. We still have purchase agreements in place for other types of vaccines.

All agreements are subject to the vaccines successfully completing all clinical trials and passing regulatory approvals in New Zealand before they will be provided to the community.

Pfizer/BioNTech (Comirnaty)

Type of vaccine: mRNA-based vaccine
Doses needed: 2
Number of doses agreed to: 10 million
Status: Provisional approval, with conditions

Learn more about the Pfizer/BioNTech vaccine

Janssen Pharmaceutica

Type of vaccine: Viral vector vaccine
Doses needed: 1
Number of doses agreed to: Up to 5 million
Status: Application received, some data under evaluation, further data to be provided.

Agreement advanced to purchase up to 5 million COVID-19 vaccines (external link)

University of Oxford and AstraZeneca

Type of vaccine: Viral vector vaccine
Doses needed: 2
Number of doses agreed to: 7.6 million
Status: Application received, some data under evaluation, further data to be provided.

Two new vaccines secured, enough for every New Zealander (external link)

Novavax

Type of vaccine: Protein subunit vaccine
Doses needed: 2
Number of doses agreed to: 10.72 million

Two new vaccines secured, enough for every New Zealander (external link)

Last updated: